TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03511196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adaptive Androgen Deprivation Therapy (ADT)
Description: ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Prednisone 5 mg once a day with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Abiraterone 1000 mg daily with empty stomach.
Study: NCT02425345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
Study: NCT01290575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 15mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 60mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, oral, 150mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 300mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 450mg, twice daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, To be determined (TBD), once daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, To be determined (TBD), once daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, To be determined (TBD), once daily, 14 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 5 mg, twice daily, 14 day
Study: NCT02334826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI -BVS
Description: All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
Study: NCT00736294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
Study: NCT03253536

Intervention type: OTHER
Intervention: observational
Description: none (observational study)
Study: NCT00913211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor learning training
Description: one hour of repeated finger tracking movements toward a changing target.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS and Tracking
Description: Combination of rTMS and finger tracking

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Sham treatment of rTMS
Study: NCT00604747

Intervention type: OTHER
Group type: OTHER
Intervention: Structure practice
Description: there were 2 groups which received random practice and constant practice during acquisition phase
Study: NCT04633772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Intravenous supplementation of Angiotensin-(1-7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%
Study: NCT03163537

Intervention type: DEVICE
Intervention: HealthPatch
Description: Smart patch that is able to measure stress real time using an algorithm between HR and HRV

Intervention type: DEVICE
Intervention: HealthPatch
Description: Smart patch that is able to measure stress real time using an algorithm between HR and HRV

Intervention type: DEVICE
Intervention: HealthPatch
Description: Smart patch that is able to measure stress real time using an algorithm between HR and HRV
Study: NCT00994227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy for macular disease
Description: three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
Study: NCT01744158

Intervention type: OTHER
Intervention: No intervention applicable
Description: Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history
Study: NCT01616160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: 2 sprays/nostril BID
Study: NCT01925976

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized dietetic intervention-eating habits
Description: The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
Study: NCT03328598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology therapy group
Description: This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience promotion therapy group
Description: The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled routine activity
Description: Conventional community activities is viewed as an active comparator for controlled group.
Study: NCT02362737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Brotherhood (AHB)
Description: Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
Study: NCT04497012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg/kg/day Iron Sulfate
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 mg/kg/day Iron Sulfate
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Study: NCT04151199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EE Training
Description: Participants randomized to EE training engage in three school-based or center-based (PERC) EE training sessions each week for approximately 12 weeks; each session lasting roughly 70 min with a 45-50 minutes of a stimulus phase and the remaining time being used to warm-up and cool down.
Study: NCT02912559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT00717652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbutin, tretinoin, triamcinolone
Description: arbutin, tretinoin, triamcinolone
Study: NCT02912559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00717652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triluma
Description: Hydroquinone, Fluoncinolone, Tretinoin
Study: NCT02745483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separable clustered electrodes
Description: patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
Study: NCT01100632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng, vitamins, minerals
Description: 2 capsules per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Gelatin capsule
Description: 2 capsules per day
Study: NCT04030234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment group
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP treatment group
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Study: NCT00401518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-randomized ACADIA® Facet Replacement System
Description: Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
Study: NCT02912559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01274338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02248077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoloGel

Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care (UCC)
Study: NCT04401566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal myofascial release
Description: Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External myofascial release
Description: Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
Study: NCT03738332

Intervention type: DEVICE
Group type: OTHER
Intervention: Low-Level Laser
Description: Low-level laser therapy
Study: NCT04041609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: A single administration of LYR-210 depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: A single administration of LYR-210 depot

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator
Study: NCT01825109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
Study: NCT02983448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
Study: NCT01133821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPSRT plus placebo (IPSRT-PLA)
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPSRT plus quetiapine
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Study: NCT03977584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [^18F]GTP1
Description: IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
Study: NCT01274338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV and SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV and SC
Study: NCT02639273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Active Drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose Placebo
Study: NCT01534598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FdCyd + THU
Description: Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
Study: NCT03646045

Intervention type: OTHER
Intervention: Transpyloric feeding
Description: Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
Study: NCT01167712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery